Ezetimibe Plus Moderate-dose Simvastatin After Acute Coronary Syndrome: What Are We IMPROVEing On? Article

Full Text via DOI: 10.1016/j.amjmed.2015.01.034 PMID: 25731133 Web of Science: 000358388500037
International Collaboration

Cited authors

  • DiNicolantonio, James J.; Chatterjee, Subhankar; Lavie, Carl J.; Bangalore, Sripal; O'Keefe, James H.


  • The recent IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) is the first study to demonstrate a significant benefit of another medication (ezetimibe) on top of statin therapy in patients who have recently experienced an acute coronary syndrome. Despite the fact that ezetimibe led to positive results on the primary endpoint, the clinical benefit translated to real-life practice is only modest at best. However, this is the first major trial to demonstrate a significant benefit of a lipid medication in addition to statins. We explore the strengths and weaknesses of IMPROVE-IT in the context of current-day acute coronary syndrome practice, where high-dose statins now are prescribed widely. (C) 2015 Elsevier Inc. All rights reserved.

Publication date

  • 2015

Published in

International Standard Serial Number (ISSN)

  • 0002-9343


  • 128


  • 8